Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

BACKGROUND: Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection. METHODS: Nineteen Belgian hospitals identified all patients with a history of solid cancer hospitalized with COVID-19 between March 2020 and February 2021. Demographic, cancer-specific and COVID-specific dat... Mehr ...

Verfasser: Geukens, T
Brandão, M
Laenen, A
Collignon, J
van Marcke, Cédric
Louviaux, I
Demey, W
Van Wambeke, S
Schrijvers, D
Lecomte, S
Mebis, J
Rutten, A
Fontaine, C
Lybaert, W
Aspeslagh, S
Goeminne, Jean-Charles
Van Den Bulck, H
Seront, Emmanuel
De Backer, L
De Roock, W
Ignatiadis, M
Prenen, H
Van Beckhoven, D
Heijlen, M
Verheezen, J
Rottey, S
Punie, K
de Azambuja, E
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Verlag/Hrsg.: Elsevier
Schlagwörter: Humans / COVID-19 / Belgium / SARS-CoV-2 / Retrospective Studies / COVID-19 Testing / Lung Neoplasms / Medical Oncology / Registries / cancer / prognosis / solid tumours / treatment changes
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26588385
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/270380